AI주식인사이트AI Stock Insight
C

일양약품

007570KOSPI

52.5 / 100

Reference Date: 2026-09-08

Financial Score19.5 / 40
News Sentiment18.0 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly down 2.0% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Ilwang Pharm focuses on developing innovative drugs like 'Noltek' (ulcer treatment) and 'Sufekt' (leukemia treatment), expanding into global markets, and strengthening long-term growth through R&D investments. In 2022, the company reported consolidated sales of 2.724 trillion KRW and operating profit of 49 billion KRW, with ongoing market expansion in China and Mexico.

Number of Employees

665people

Average Salary

84.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
22.21Industry Average 15.003.0Point

Higher than industry avg (caution)

PBR
0.66Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
2.97Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
18.54Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲0.3% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼43.9% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 2.2% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 3Neutral 0Negative 4Average Sentiment Score 72.1

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 8,330Won52-week high 13,63052-week low 7,320
1-month return3.0Point

1m -2% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-08-21
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-08-21
  • Neutral반기보고서 (2026.06)2026-08-14